SCHEMBL807928

SCHEMBL807928

Cc1ccc(F)c(Nc2nc(N)nc(-c3noc(-c4ccco4)n3)n2)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LCLAT1 Q6UWP7 2/20 0.43
NPC1 O15118 10/20 0.41
RAB9A P51151 10/20 0.41
SMN1; SMN2 Q16637 6/20 0.41
HSD17B10 Q99714 5/20 0.41
ALDH1A1 P00352 5/20 0.41
HPGD P15428 4/20 0.41
MAPT P10636 3/20 0.41
KDM4E B2RXH2 3/20 0.41
USP2 O75604 3/20 0.41
NFKB1 P19838 2/20 0.41
NFKB2 Q00653 2/20 0.41
RELA Q04206 2/20 0.41
NPSR1 Q6W5P4 1/20 0.41
CASP3 P42574 3/20 0.41
ADORA2A P29274 2/20 0.41
TP53 P04637 4/20 0.40
MEN1 O00255 3/20 0.40
KMT2A Q03164 3/20 0.40
MAPK1 P28482 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL795710 0.89 CASP3 (0.43) NPC1RAB9ASMN1; SMN2HSD17B10ALDH1A1
SCHEMBL796526 0.88 CASP3 (0.50) LCLAT1NPC1RAB9ASMN1; SMN2HSD17B10
SCHEMBL795322 0.82 NPC1 (0.43) NPC1RAB9ASMN1; SMN2HSD17B10ALDH1A1
SCHEMBL796382 0.82 NPC1 (0.41) LCLAT1NPC1RAB9ASMN1; SMN2HSD17B10
SCHEMBL795193 0.78 CASP3 (0.44) NPC1RAB9ASMN1; SMN2HSD17B10ALDH1A1
SCHEMBL795357 0.78 ADORA2A (0.47) NPC1RAB9ASMN1; SMN2HSD17B10ALDH1A1
SCHEMBL795418 0.78 SMN1; SMN2 (0.41) LCLAT1NPC1RAB9ASMN1; SMN2HSD17B10
SCHEMBL795637 0.78 MAPT (0.43) NPC1RAB9ASMN1; SMN2HSD17B10ALDH1A1
SCHEMBL795831 0.77 CASP3 (0.48) LCLAT1NPC1RAB9ASMN1; SMN2HSD17B10
SCHEMBL795092 0.71 RAB9A (0.43) NPC1RAB9ASMN1; SMN2HSD17B10ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2616465-B1 TRIAZINE-OXADIAZOLES NOVARTIS AG (CH) 2015-11-04 EP disclosed
US-20150025057-A1 Triazine-oxadiazoles NOVARTIS AG (CH) 2015-01-22 US disclosed
US-8895733-B2 Triazine-oxadiazoles NOVARTIS AG (CH) 2014-11-25 US disclosed
US-20140051676-A1 Triazine-oxadiazoles NOVARTIS AG (CH) 2014-02-20 US disclosed
WO-2012035023-A1 TRIAZINE-OXADIAZOLES NOVARTIS AG (CH) 2012-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150025057-A1 Triazine-oxadiazoles OPRK1, OPRD1, OPRL1 LCLAT1 3387/4885NPC1 3204/4885RAB9A 4766/4885
US-20140051676-A1 Triazine-oxadiazoles OPRK1, OPRD1, OPRL1 LCLAT1 3387/4885NPC1 3204/4885RAB9A 4766/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.